Welcome to our dedicated page for Xtant Medical SEC filings (Ticker: XTNT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Xtant Medical Holdings, Inc. (XTNT) SEC filings page on Stock Titan provides structured access to the company’s regulatory disclosures, including current reports, proxy statements, and financial updates filed with the U.S. Securities and Exchange Commission. Xtant is a global medical technology company focused on orthobiologics for chronic and surgical wound care and sports medicine markets, as well as spinal implant systems for spinal and other orthopedic conditions, and its filings offer detailed insight into how this business is governed and financed.
Among the key documents available are Form 8-K current reports, where Xtant discloses material events. For example, an 8-K dated December 3, 2025 describes the completion of the sale of certain Coflex and CoFix spinal implant assets and all shares of Paradigm Spine GmbH, its international hardware business, to Companion Spine entities, along with related use of proceeds and pro forma financial information. Other 8-Ks report quarterly financial results, the use of non-GAAP adjusted EBITDA, changes to the Board of Directors, the establishment of the annual meeting date, and risk factor updates linked to strategic transactions.
Investors can also review definitive proxy statements on Schedule 14A, such as the document filed on September 15, 2025. That proxy statement outlines the agenda for the annual meeting of stockholders, including director elections, ratification of the independent registered public accounting firm, an amendment to the 2023 Equity Incentive Plan, and advisory votes on executive compensation and its frequency. It also describes corporate governance guidelines, board structure, director and executive compensation, and ownership information.
Through Stock Titan, these XTNT filings are updated as they appear on EDGAR and are accompanied by AI-powered summaries designed to explain the main points in accessible language. Users can quickly see what each filing covers—such as divestiture terms, debt prepayments, equity plan changes, or non-GAAP metric definitions—without reading every page in full.
For those tracking financial performance and capital structure, the filings include condensed consolidated balance sheets, income statement data, and discussions of liquidity, debt arrangements, and credit facility consents. Governance-focused readers can examine voting results from the annual meeting, details of equity incentive plan amendments, and disclosures about significant shareholders and board composition.
By using this XTNT filings page, investors, analysts, and researchers can navigate Xtant Medical’s regulatory history, understand the implications of its asset sales and biologics-focused strategy, and interpret recurring topics such as non-GAAP adjusted EBITDA and risk factors, with AI tools helping to highlight the most important elements in each submission.
Xtant Medical Holdings, Inc. files its Annual Report describing a spine-focused medical technology business built around orthobiologics and spinal implant fixation systems sold mainly in the United States through over 670 independent sales and stocking agents.
In 2025 the company recognized $18.7 million of license revenue that it states will likely not repeat in 2026 due to reimbursement changes affecting its SimpliMax and SimpliGraft products, which it expects will also reduce a portion of product revenue and pressure gross margins. Xtant completed two divestitures on December 1, 2025, selling Coflex and CoFix product assets and its Paradigm Spine GmbH international hardware business to Companion Spine for aggregate consideration of $21.4 million
The report details an extensive orthobiologics and spinal hardware portfolio, a large patent estate, significant regulatory and reimbursement exposure, and numerous risk factors including dependence on donor tissue, independent distributors, government payors, and compliance with complex U.S. and international medical device regulations. As of December 31, 2025, Xtant employed 151 full-time staff across operations, sales and marketing, R&D, quality, regulatory, and administrative roles.
Xtant Medical Holdings, Inc. reported a strong turnaround for 2025, shifting to profitability while reshaping its portfolio. Full-year 2025 revenue reached $133.9–$134.0 million, up about 14% from 2024, driven by higher license revenue and growth in its core biologics business.
Net income for 2025 improved to $5.0 million, or $0.03–$0.04 per share, compared with a prior-year net loss of $16.5 million. Non-GAAP adjusted EBITDA rose to $16.3 million from a loss of $2.3 million, reflecting better gross margins of 62.9% and lower operating expenses. Cash and restricted cash increased to $17.3 million at year-end, supported by divesting non-core Coflex/CoFix assets and an international hardware business.
For 2026, the company expects revenue between $95 million and $99 million, as organic growth in higher-margin biologics is offset by the December 2025 divestitures and the end of 2025 license revenue streams. Management highlighted a term loan balance of $11.2 million and a current cash position above $22 million, and it expects to be free cash flow positive in 2026 without raising additional outside capital.
Xtant Medical Holdings, Inc. reported receiving a $10.7 million payment from Companion Spine on February 27, 2026. This payment covered full repayment of an $8.2 million unsecured promissory note, accrued interest, and net working capital and other purchase price adjustments related to prior divestitures.
These divestitures involved certain Coflex and CoFix assets and all shares of Paradigm Spine GmbH and now total an aggregate purchase price of $21.4 million. Xtant used $2.8 million of the proceeds to prepay part of its term loan with MidCap Financial Trust, leaving $11.1 million of principal outstanding.
Xtant Medical Holdings Chief Operating Officer Mark A. Schallenberger reported a tax-related share disposition. On this Form 4, 7,709 shares of common stock at $0.58 per share were withheld by the company to cover tax obligations upon vesting and settlement of restricted stock units. After this withholding, he reports ownership of 663,157 shares of common stock, which includes large blocks of RSU and DSU awards that will vest only if he remains employed through future vesting dates.
Laurence W. Lytton and the Lytton-Kambara Foundation report significant holdings of Xtant Medical Holdings, Inc. common stock on an amended Schedule 13G. Lytton is deemed to beneficially own 7,702,002 shares, or 5.5% of the class, while the foundation holds 7,026,104 shares, or 5.0%.
Lytton has sole voting and dispositive power over 675,898 shares and shared voting and dispositive power over 7,026,104 shares through the foundation. The percentages are calculated based on 140,004,240 shares outstanding as of November 7, 2025. The filing certifies the securities are not held to change or influence control.
Xtant Medical Holdings CFO and Assistant Secretary Neils C. Scott reported an automatic tax-withholding transaction in company stock. On 01/15/2026, 8,084 shares of common stock were withheld by the issuer at $0.65 per share to cover tax obligations triggered by the vesting and settlement of restricted stock unit awards.
After this transaction, Scott beneficially owned 843,381 shares of Xtant, which includes 498,914 shares issuable upon vesting and settlement of RSU or DSU awards under the Amended and Restated 2023 Equity Incentive Plan and 62,974 shares issuable upon vesting and settlement of RSU awards under the Amended and Restated 2018 Equity Incentive Plan, in each case conditioned on continued employment through the respective vesting dates.
Xtant Medical Holdings reports an amendment to the financing terms tied to its prior divestitures of the Coflex/CoFix product assets and Paradigm Spine GmbH to Companion Spine. The original $17.5 million Coflex/CoFix divestiture included an unsecured promissory note of $8.2 million from Companion Spine, initially due on January 15, 2026. On January 15, 2026, the parties extended this note’s maturity date to January 31, 2026. At the same time, they revised the Paradigm Spine GmbH sale agreement to move payment of the estimated positive purchase price adjustment of $1,742,000 from January 15, 2026 to January 31, 2026, aligning both obligations on the same later date.
Xtant Medical Holdings has completed two divestitures to Companion Spine involving its Coflex/CoFix product assets and its Paradigm Spine GmbH subsidiary. The Coflex/CoFix asset sale carried a total purchase price of $17.5 million, including $7.5 million of prior non‑refundable deposits, $1.8 million of cash at closing, and an $8.2 million unsecured promissory note maturing on January 15, 2026, all subject to an inventory-based adjustment. The Paradigm Spine GmbH equity sale had a total purchase price of $1.7 million, payable in cash and subject to later working-capital and other adjustments that can either increase cash received or reduce the note’s principal.
Under its credit agreement with MidCap Financial Trust, Xtant used approximately $8.0 million of net cash proceeds from these transactions to prepay part of its term loan, leaving $14.4 million outstanding as of December 1, 2025, with up to an additional $1.6 million prepayment required if the Companion Spine note is repaid.
Xtant Medical Holdings, Inc. director reports updated equity holdings through an amended Form 4. The filing shows the grant of 158,228 shares of common stock in the form of deferred stock units (DSUs) at a price of $0 on 11/15/2025 under the Amended and Restated 2023 Equity Incentive Plan. These DSUs will vest on November 15, 2026, if the individual continues to serve as a director through that date, and each DSU represents a contingent right to receive one share of common stock. Following this transaction, the reporting person beneficially owns 914,116 shares, which includes 465,570 shares issuable upon settlement of outstanding DSU awards, each subject to service-based vesting. The amendment states that its purpose is to correct the number of shares shown as beneficially held in the ownership column.
Xtant Medical Holdings, Inc. director equity grant reported
A director of Xtant Medical Holdings, Inc. (XTNT) reported receiving 553,797 shares of common stock on November 15, 2025 through a deferred stock unit (DSU) award under the company’s Amended and Restated 2023 Equity Incentive Plan. The DSUs will vest on November 15, 2026, provided the director remains on the board through that date, and each DSU represents a contingent right to receive one share of common stock, with settlement deferred to a later date under the award terms.
Following this award, the director beneficially owns 7,515,570 shares on a direct basis, which includes 1,520,215 shares issuable upon settlement of DSUs that are subject to continued service-based vesting conditions.